63rd Annual Society of Hematology Annual Meeting and Exposition to Feature New Outcomes Research from Analysis Group

December 10, 2021

Analysis Group’s Health Care practice will present one oral session and four research posters at the 63rd Annual Society of Hematology (ASH) Annual Meeting and Exposition, which will be held December 11 to 14, 2021, in Atlanta, Georgia and online. All in-person sessions will take place at the Georgia World Congress Center.

The oral session, titled “A Matching-Adjusted Indirect Comparison of Isatuximab Plus Carfilzomib and Dexamethasone Versus Daratumumab Plus Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma,” will present research by an Analysis Group team – including Vice President Jenny Zhou and Manager Viviana García-Horton – in collaboration with a team from Sanofi. The session will take place on Saturday, December 11, from 5:30 to 6:30 p.m., in Room B308-309.

Research poster presentations will include:

  • “Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Maral DerSarkissian, Senior Associate Rose Chang, Senior Analyst Yuqian Gu, and Analyst Helen Guo – in collaboration with a team from AstraZeneca. The poster will be on display Sunday, December 12, from 6:00 p.m. to 8:00 p.m., in Hall B5.
  • “Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Wendy Cheng, and Associates Chi Gao and Mu Cheng – in collaboration with a team from Novartis. The poster will be on display Monday, December 13, from 6:00 PM to 8:00 p.m., in Hall B5.
  • “Treatment Patterns and Outcomes of Patients with Double-ClassRefractory or Triple-Class Refractory Multiple Myeloma: A Retrospective US Electronic Health Record Database Study,” coauthored by an Analysis Group team – Managing Principal Mei Sheng Duh, Vice President Maral DerSarkissian, Senior Associate Rose Chang, Senior Analysts Christopher Yee and Ahmed Norman, and Analyst Anamika Khanal – in collaboration with a team from AstraZeneca. The poster will be on display Sunday, December 12, from 6:00 PM to 8:00 p.m., in Hall B5.
  • “Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy,” coauthored by an Analysis Group team – including Vice Presidents Hongbo Yang and Yan Song and Associate Mo Zhou – in collaboration with a team from Astellas Pharma. The poster will be on display Sunday, December 12, from 6:00 to 8:00 p.m., in Hall B5.

Read more about ASH’s Annual Meeting